Safety and Vascular Remodelling After BVS Implantation for Stenotic or Occluded Lesions in Children and Young Adults With KD.

Learn more about:
Related Clinical Trial
Clinical Precise Diagnosis and Treatment in the Kawasaki Disease A Blood Test to Diagnose Kawasaki Disease Defibrotide in Children With High Risk Kawasaki Disease Pilot Study of Atorvastatin and Anakinra in Children With Coronary Artery Abnormalities Secondary to Kawasaki Disease A Randomized Phase III Multicenter Trial Comparing the Efficacy and Safety of Anakinra Versus Intravenous Immunoglobulin (IVIG) Retreatment, in Patients With Kawasaki Disease Who Failed to Respond to Initial Standard IVIG Treatment Characterization of Multisystem Inflammatory Syndrome in Children (MIS-C) and Its Relationship to Kawasaki Disease Efficacy of Immunoglobulin Plus Infliximab for the Early Regression of Coronary Artery Lesion in Kawasaki Disease Methylprednisolone Pulse Therapy for Coronary Artery Dilatation or Aneurysm Formation in Kawasaki Disease Statins Study in Kawasaki Disease Children With Coronary Artery Abnormalities Doxycycline Treatment to Prevent Progressive Coronary Artery Dilation in Children With Kawasaki Disease A Trial to Evaluate the Efficacy of Immunoglobulin Plus Steroid for Prevention of Coronary Artery Abnormalities in Taiwanese Refractory Kawasaki Disease (RAST Study) Prevention of Coronary Aneurysms in Kawasaki Syndrome A Trial to Determine Radiation Exposure to Organs and Assess the Safety of CARDIOLITE® in Pediatric Subjects Real Time Myocardial Contrast Echocardiography and Dobutamine Stress Perfusion Magnetic Resonance Imaging Study of Efficacy and Safety of Canakinumab in Pediatric Patients With Kawasaki Disease Trial of Atorvastatin on the Persistent Coronary Aneurysm in Children With Kawasaki Disease Anakinra and Kawasaki Disease Study of Combined Therapy of Aspirin and “IVIG-SN” in Kawasaki Disease Study of Combined Therapy IVIG-SN 10% and Acetylsalicylic Acid in Kawasaki Disease Cardiovascular Status of Children 5 Years After Kawasaki Disease Safety and Vascular Remodelling After BVS Implantation for Stenotic or Occluded Lesions in Children and Young Adults With KD. A Multi-center, Randomized to Compare the Efficacy of IVIG Alone and IVIG Plus High-dose Aspirin in Kawasaki Disease Etanercept in Kawasaki Disease Efficacy of Immunoglobulin Plus Prednisolone in Reducing Coronary Artery Lesion in Patients With Kawasaki Disease Cardiovascular Risk Markers and Response to Statins After Kawasaki Disease Anakinra in Infants and Children With Coronary Artery Abnormalities in Acute Kawasaki Disease Infliximab (Remicade) for Patients With Acute Kawasaki Disease Acute Abdomen in Kawasaki Disease Infliximab Plus Intravenous Immunoglobulin for the Primary Treatment of Kawasaki Disease Epidemiologic Features of Kawasaki Disease in Shanghai From 2013 Through 2017 Different Doses of IVIG for Kawasaki Disease Pharmacokinetics (PK)/Safety Study of Atorvastatin in Children With Kawasaki Disease and Coronary Artery Abnormalities Epidemiologic Features of Kawasaki Disease in Shanghai From 2008 Through 2012 Measurement of Antibodies in Adults With a History of Kawasaki Disease Prevalence and Early Markers of Atherosclerosis in Adults With a History of Kawasaki Disease A Study to Evaluate the Use and Safety of CARDIOLITE® in Pediatric Patients With Kawasaki Disease Genetic Determinants of Kawasaki Disease Infliximab for Kawasaki Disease Patients Resistant to IVIG : a Multicentre, Prospective, Randomised Trial KIDCARE (Kawasaki Disease Comparative Effectiveness Trial) Multi-center Prospective Randomized Control Trail of High Dose Aspirin in Acute Stage of Kawasaki Disease

Brief Title

Safety and Vascular Remodelling After BVS Implantation for Stenotic or Occluded Lesions in Children and Young Adults With KD.

Official Title

Safety and Vascular Remodelling After Bioresorbable Vascular Scaffold Implantation for Stenotic or Occluded Lesions in Children and Young Adults With Kawasaki Disease

Brief Summary

      To investigate the safety and long-term vascular remodeling after bioresorbable vascular
      scaffold (BVS) implantation for stenotic or occluded lesion in children or young adults with
      Kawasaki disease (KD).

      Background: KD occurs worldwide, most prevalent in Japan and East Asian countries. Coronary
      artery lesion is the predominant determinant of KD outcome in the long-term. Children with KD
      with aneurysms at least 6 mm in maximal diameter had a greater than 50% chance of developing
      a clinically significant stenotic lesion during follow-up. They are at risk of myocardial
      infarction-related sudden death or congestive heart failure as young adults. Bypass surgery
      could be the reasonable strategy but the long-term patency of the graft remains
      unsatisfactory. Percutaneous angioplasty with drug-eluting stents (DES) implantation is the
      alternative. However, metallic stenting remains problematic in several aspects mainly due to
      the restriction of vessel expansive remodeling. The novel BVS has the potential to be free
      from the limitation due to scaffold degradation.
    

Detailed Description

      we will conduct a single-center, single-group prospective study with safety and imaging
      endpoints. A total of 10 KD children or young adults with indication of revascularization are
      enrolled, and BVS will be implanted for stenotic or occluded lesions. QCA and optical
      coherence tomography (OCT) are used to evaluate the baseline lumen area, plaque
      characteristics, and BVS expansion or eccentricity after deployment. At 12 months, scaffold
      restenosis is evaluated by multislice computed tomography. At 30 months, patients will
      receive follow-up by angiography and OCT to evaluate lumen area, neoplaque characteristics,
      and side branch conditions. Otherwise, the composite endpoint including cardiac death,
      myocardial infarction, and ischaemia-driven target lesion revascularisation are assessed at
      30 days, 6 and 9 months, and 1, 2, 3 years.
    


Study Type

Interventional


Primary Outcome

time to disease progression


Condition

Kawasaki Disease

Intervention

Bioresorbable Vascular Scaffold

Study Arms / Comparison Groups

 Kawasaki disease
Description:  

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Device

Estimated Enrollment

10

Start Date

February 2016

Completion Date

February 2019

Primary Completion Date

February 2019

Eligibility Criteria

        Inclusion criteria:

          1. In the single-group prospective study with safety and imaging endpoints, a total of 10
             KD patients < 18 years will be enrolled.

          2. The diagnosis of KD was made based on clinical criteria for KD.

        Exclusion criteria:

        Patients presenting with an acute myocardial infarction or unstable arrhythmias, or those
        who has severe left ventricular dysfunction (ejection fraction less than 35%), intrastent
        restenotic lesions, lesions located in the left main coronary artery, and tight lesions
        which could not be well dilated even after rotational atherectomy are excluded. Those with
        chronic renal insufficiency (creatinine >1.5 mg/dl) are also excluded due to the limitation
        of OCT (optical coherence tomography) use.
      

Gender

All

Ages

10 Years - 18 Years

Accepts Healthy Volunteers

No

Contacts

Wang Yi-Chih, 886-972652218, [email protected]

Location Countries

Taiwan

Location Countries

Taiwan

Administrative Informations


NCT ID

NCT02771288

Organization ID

201512126DINC


Responsible Party

Sponsor

Study Sponsor

National Taiwan University Hospital


Study Sponsor

Wang Yi-Chih, Principal Investigator, NTUH


Verification Date

May 2016